Global Minimal Residual Disease Market Size, Trend & Opportunity Analysis Report, by Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Flow Cytometry, Others), Cancer Type (Haematological Malignancy (Leukemia, Lymphoma), Solid Tumors), End Use (Academic and Research Institutes, Diagnostics Laboratories, Hospitals and Specialty Clinics, Others), and Forecast, 2025-2035
Global Minimal Residual Disease Market Size, Opportunity Analysis and Forecast, 2025-2035
Market Definition and Introduction
The Global Minimal Residual Disease (MRD) Market was valued at USD 2.35 billion in 2024 and is anticipated to reach USD 7.82 billion by 2035, expanding at a CAGR of 11.55% during the forecast period 2025-2035. The minimal residual disease (MRD) marketplace now updates the orders of management when it comes to cancer as precision oncology progresses. The new developments have provided methods for clinicians to analyse risks of relapse with very superior accuracy. Increasing reliance on very sensitive technologies, like next-generation sequencing (NGS) and polymerase chain reaction (PCR), transforms MRD detection from a research-based adjunct to a necessity in clinical routine. They are pushing the diagnostic thresholds lower, giving scope for very early interventions to bring down relapse rates and optimise
survival over the whole range of haematological malignancies.
Paradigm shifts in medicine towards personalised treatments have further strengthened the place of MRD measurement as a key biomarker relative to therapy decisions, especially in leukaemias, myelomas, and lymphomas. Within this premise, healthcare givers are increasingly practising MRD-based therapy, and payers are warming up to the longevity of cost-effectiveness, thus hastening mainstreaming into standard pathways of care. Pharmaceutical companies are also starting to incorporate MRD endpoints into their clinical trial designs and thus revolutionising drug development strategies to ones bearing verifiable measures of treatment effectiveness and marginal disease progression.
Diagnostic developers and biotech innovators have been widening their portfolios with high-throughput ultra-sensitive platforms capable of handling various cancer profiles subject to extremely tough regulatory approvals. The companies tie themselves into increasing partnerships with oncology centres and hospitals to ensure clinical validation, regulatory clearance, and market penetration. Such rapid metamorphosis pushes competitive differentiation and improves investments, making MRD testing a growth driver in precision diagnostics and oncology over the long run.
Recent Developments in the Industry
- In March 2024, Adaptive Biotechnologies announced the use of its platform clonoSEQ- for one more haematological cancer, with regulatory approvals that further highlight the role it plays in precision diagnostics and extend reimbursement coverage across major markets around the globe.
- In January 2025, Natera Inc. received further approval for reimbursement of its Signatera test; this was a huge step toward opening up access to personal MRD testing in haematological malignancies and solid tumours under clinical guidelines.
- In June 2024, F. Hoffmann-La Roche Ltd went into a strategic agreement with several major oncology centres in Europe to produce decentralised, PCR-based solutions for the identification of MRD as part of their resolve to enhance real-time access to testing across hospital networks.
- In April 2023, Bio-Rad introduced next-generation droplet digital PCR technology featuring higher precision and non-variable reproducibility so that MRD detection is even more efficient in leukaemia and lymphoma laboratories.
- In August 2024, Thermo Fisher Scientific launched a new diagnostic portfolio platform based on advanced NGS specifically designed to provide more efficient workflows for MRD testing, incorporating automation and bioinformatics pipelines to speed turnaround times and clinical uptake.
Market Dynamics
Rising Clinical Adoption of MRD Testing Revolutionises Cancer Monitoring and Treatment Decisions
The gradual embedding of MRD testing into clinical practice is changing treatment paradigms for haematological malignancies. With earlier relapse detection and measurable outcomes, MRD is emerging as a gold standard biomarker in oncology. Certainly, pharmaceutical companies are now using MRD data increasingly to design adaptive clinical trials that shorten drug approvals and substantiate the generation of real-world evidence. The increasing recognition by clinicians and payors regarding the cost-effectiveness of MRD testing contributes to its market growth.
Regulatory approvals and reimbursement expansion hasten bringing products to the market worldwide.
Payers in North America and Europe are starting to grant reimbursement for some MRD assays, such as Natera's Signatera and Adaptive's clonoSEQ. Such financial backing has provided much-needed access to patients and encouraged hospitals to embed testing into their oncology protocols. Further, regulators are updating guidelines to enforce or encourage MRD-based monitoring in certain blood cancers, supporting the drive for adoption.
High costs, data interpretation challenges, and infrastructure gaps threaten large-scale.
Yet, while very lucrative, realisation of the potential of MRD testing is hindered by high costs, complex data interpretation, and infrastructural barriers. Advanced NGS platforms necessitate a capital-hungry laboratory setup, trained personnel, and high-end bioinformatics, which in most developing markets are scanty. Besides, the different standardisation across platforms creates heterogeneous interpretation challenges, adding to the complexities in establishing a global benchmark.
Beyond the growing pipeline of MRD-guided therapies, increasing opportunities exist.
Opportunities for the creation of MRD-guided therapies have emerged as biopharmaceutical representatives have put MRD endpoints in drug development. Such targeting therapies possess the capacity to change treatment pathways, eradicate meaningless toxic exposures, and thus enhance survival rates, providing attractive opportunities for diagnostic-drugs partnerships.
Machine learning and AI in bioinformatics and digital pathology will accelerate the growth trajectory of the market.
Emerging trends will see AI and machine learning working to improve MRD data interpretation. With the help of powerful algorithms, real-time analysis of data, automated variant calling, and minimisation of human error are made possible. This integration is pushing MRD testing for wider adoption in clinics, establishing itself as a pillar of precision medicine.
Attractive Opportunities in the Market
- NGS Expansion Potential - Expanding next-generation sequencing workflows offers unmatched sensitivity and wider diagnostic coverage.
- PCR Innovation Drive - Ultra-sensitive PCR innovations enable scalable MRD adoption in hospital and laboratory settings.
- Regulatory Reimbursement Wins - Expanding coverage across payers and governments boosts global patient accessibility.
- MRD-Guided Therapies - Integration of MRD biomarkers in trials accelerates targeted therapy development pathways.
- AI-Powered Analysis - Artificial intelligence platforms enhance precision, turnaround, and clinical decision-making capabilities.
- Haematological Focus Surge - Rising prevalence of leukaemia and lymphoma amplifies MRD test demand globally.
- Emerging Market Adoption - Growing investments in Asia-Pacific create promising new growth frontiers for MRD solutions.
- Hospital-Lab Collaborations - Strategic alliances enable decentralised testing and stronger patient reach across regions.Pharma-Diagnostic Partnerships - Joint development ensures seamless clinical trial support and commercial test validation.
- Digital Health Integration - MRD linked with digital monitoring tools augments personalised cancer care delivery.
Report Segmentation
By Technology: Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Flow Cytometry, Others
By Cancer Type:
- Haematological Malignancy (Leukemia, Lymphoma)
- Solid Tumors
By End Use: Academic and Research Institutes, Diagnostics Laboratories, Hospitals and Specialty Clinics, Others
By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
Key Market Players: Adaptive Biotechnologies, Natera Inc., Invitae Corporation, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., Guardant Health, ArcherDX (a part of Invitae), Sysmex Corporation, Thermo Fisher Scientific Inc., and Qiagen N.V.
Report Aspects
Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2024-2035
Report Pages: 290
Dominating Segments
NGS technology segment dominates the MRD market with unmatched sensitivity and clinical utility
Next-generation sequencing (NGS) holds a commanding position in the MRD market, attributed to its ability to detect extremely low levels of residual cancer cells with unparalleled precision. Clinicians and researchers prefer NGS because it can interrogate thousands of genetic markers simultaneously, ensuring highly accurate monitoring across diverse haematological malignancies. Despite higher costs, its scalability, depth of information, and integration into biopharma clinical trials reinforce NGS as the cornerstone of MRD testing worldwide. Increasing adoption across developed economies, alongside ongoing reimbursement approvals, ensures its sustained dominance in the coming decade.
PCR segment remains critical due to cost efficiency and hospital-scale accessibility
Polymerase chain reaction (PCR) continues to play a vital role, particularly in resource-constrained settings and routine hospital environments. Its comparatively lower cost, faster turnaround time, and proven reliability ensure PCR remains widely utilised in MRD detection. Furthermore, innovations in digital droplet PCR (ddPCR) have boosted sensitivity levels, bringing PCR closer to NGS standards in performance. Its integration into decentralised testing workflows and strong demand in emerging markets are expected to preserve its importance as a
complementary technology.
Haematological malignancies segment leads the MRD market adoption across the oncology spectrum.
Haematological malignancies, including leukaemia, multiple myeloma, and lymphoma, dominate MRD applications owing to their complex relapse profiles and high prevalence. MRD testing has become indispensable in guiding treatment intensification or de-escalation for these cancers, directly influencing clinical outcomes. The integration of MRD endpoints in regulatory frameworks and treatment guidelines across North America and Europe has accelerated uptake, while rising incidence rates in the Asia-Pacific region ensure a broadening patient pool. As therapies become increasingly personalised, MRD testing for blood cancers will continue to anchor the overall market trajectory.
Key Takeaways
- NGS Dominance - Next-generation sequencing leads due to superior accuracy and integration into precision oncology.
- PCR Accessibility - PCR remains vital in cost-sensitive markets with robust digital PCR innovations.
- Haematological Focus - MRD demand rises sharply in leukaemia, lymphoma, and multiple myeloma monitoring.
- Regulatory Tailwinds - Reimbursement wins and guideline endorsements drive accelerated adoption globally.
- Pharma Integration - MRD endpoints reshape clinical trial designs and speed regulatory approvals.
- AI Synergy - Machine learning strengthens data interpretation and real-time clinical decision support.
- Emerging Market Growth - Asia-Pacific investments expand MRD adoption in cancer diagnostics infrastructure.
- Therapy Guidance - MRD testing improves relapse detection and tailors treatment strategies in oncology care.
- Commercial Partnerships - Collaborations expand decentralised MRD testing networks across hospitals and laboratories.
- Sustainability Challenge - High testing costs and infrastructural barriers remain key hurdles to global scalability.
Regional Insights
Surveying North America will reveal the greatest infrastructure and best reimbursement frameworks of any MRD market.
North America is the greatest MRD market, having a very strong oncology infrastructure and reimbursement policies, and a good level of acceptance in clinical trials as well as routine care. In this domain, the U.S. leads in regulatory approvals, payer coverage expansions, and integration of MRD into national guidelines with the help of leading biotech innovators headquartered in the region.
Europe fast-tracks acceptance with valid regulations and cooperative clinical networks.
Supported by EMA regulations, research networks promoting cancer studies on both clinical and experimental fronts can be found in Europe, attracting an early acceptance of MRD in clinical workflows. Countries such as Germany, the UK, and France have all integrated MRD considerations into haematology guidelines, with established collaborations in academia driving validation of decentralised testing solutions.
Asia-Pacific- the fastest-growing MRD market by cancer prevalence
Adoption of MRD is growing in Asia-Pacific, driven by the cause of rising cancer prevalence; Investments in diagnostic infrastructure are also increasing, while government policies push precision medicine. Countries like China, India, and South Korea are spearheading demand growth backed by partnerships that some diagnostic companies have formed with local healthcare providers.
Potent investments and awareness campaigns have built MRD detection processes in the LAMEA region.
Adoption of MRD testing is gradually expanding in Latin America, the Middle East, and Africa, even though limited infrastructure and reimbursement policies do constitute hurdles. However, targeted investment activities and awareness campaigns, together with partnerships with global diagnostic companies, are presenting new growth opportunities in emerging markets.
Key Benefits for Stakeholders
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
Frequently Asked Question(FAQ) :
Next-Generation Sequencing (NGS) is the dominating technology segment. Its leadership is attributed to its unmatched sensitivity and ability to detect extremely low levels of residual cancer cells by interrogating thousands of genetic markers simultaneously, making it the preferred choice for precision oncology and clinical trials.
While NGS leads in sensitivity, PCR remains a critical segment due to its cost-efficiency, faster turnaround times, and accessibility for routine hospital-scale testing. Innovations such as digital droplet PCR (ddPCR) are further enhancing its sensitivity, making it a vital tool in resource-constrained settings and decentralized laboratory networks.
Haematological malignancies, including leukaemia, lymphoma, and multiple myeloma, are the leading segments. MRD testing has become a gold standard for these cancers to guide treatment intensification or de-escalation. However, there is also significant emerging growth in the application of MRD testing for solid tumors.
North America is the leading market due to its advanced oncology infrastructure, favorable reimbursement frameworks (such as coverage for Natera’s Signatera and Adaptive’s clonoSEQ), and the high concentration of leading biotech innovators and clinical trials.
Growth is primarily driven by the transition toward personalized medicine, the increasing prevalence of blood cancers, expanding regulatory approvals, and the inclusion of MRD endpoints in pharmaceutical clinical trials to substantiate treatment effectiveness and accelerate drug approvals.
AI and machine learning are being integrated into bioinformatics pipelines to improve data interpretation. These technologies help automate variant calling, minimize human error, and provide real-time analysis, which is essential for scaling MRD testing in clinical routines.
The market faces hurdles such as high capital costs for NGS platforms, a lack of universal standardization across different testing methodologies, complex bioinformatics requirements, and limited infrastructure/reimbursement in developing economies.
Recent milestones include Natera Inc. and Adaptive Biotechnologies securing expanded reimbursement coverage for their respective assays, Roche entering strategic agreements for decentralized PCR solutions in Europe, and Thermo Fisher Scientific launching advanced NGS platforms with automated workflows to speed up clinical uptake.
Significant opportunities lie in the development of MRD-guided therapies, expansion into the Asia-Pacific region (the fastest-growing market due to rising cancer prevalence), and strategic partnerships between pharmaceutical companies and diagnostic developers to validate tests for commercial use.
